National

Zydus Cadila to seek nod for two-dose regimen of its approved vaccine in India

Considering the burden on healthcare and the expense of buying three doses, Zydus Cadila is planning to seek approval for the two-dose regimen of its needle-free COVID-19 vaccine, ZyCoV-D, days after the vaccine was approved by India’s drugs regulator for emergency use in India on August 20.

migrator

Updated:13th Sep, 2021 at 9:48 AM

New Delhi

The trials for the two-dose regimen are underway. 2mg of the vaccine has been prescribed in each dose of the present-day three-dose vaccine i.e. total of 6 mg. The company is now evaluating a 2 dose regime with 3mg in each dose. The vaccine is said to be pathbreaking as it is for the first time that a technologically advanced vaccine has been successfully developed on the Plasmid DNA platform for human use.

Visit news.dtnext.in to explore our interactive epaper!

Download the DT Next app for more exciting features!

Click here for iOS

Click here for Android

Zydus Cadila to seek nod for two-dose regimen of its approved vaccine in India

Considering the burden on healthcare and the expense of buying three doses, Zydus Cadila is planning to seek approval for the two-dose regimen of its needle-free COVID-19 vaccine, ZyCoV-D, days after the vaccine was approved by India’s drugs regulator for emergency use in India on August 20.

Also Read

Dravidian model 2.0 will take all sectors to new heights, vows CM Stalin

Ruling govt will be in dock for Nehru's corruption in 2 weeks: EPS

Tilak vows to raise Tamil Nadu’s voice in Upper House, focus on Tiruchy's development

Trade deal to oil, foreign policy under US mortgage: TNCC chief

Tamil Nadu clears 1,249 posts to handle poll work